Suites 10/11, Level 3,
Private Medical Centre
The Royal Melbourne Hospital
Parkville VIC 3050
Tel: 03 9342 7789
Fax: 03 9342 8500
MBBS PhD FRACP FRCPA
- Consultant Haematologist
Dr Lynette Chee graduated from Medicine at the University of Adelaide and completed her postgraduate training in Clinical and Laboratory Haematology at the Christchurch, Austin and Royal Melbourne Hospitals. She has a joint fellowship with the Royal College of Pathologists of Australasia (RCPA) and the Royal Australasian College of Physicians (RACP).
Dr Chee then undertook PhD and post-doctoral research investigating novel retinoids in the treatment of acute myeloid leukaemia at the Peter MacCallum Cancer Institute, Melbourne. Her work has been published in leading peer-reviewed medical journals, presented both at national and international conferences and awarded scholarships from the University of Melbourne, RACP and various professional haematology associations including the American Society of Hematology (ASH), Haematology Society of Australia and New Zealand (HSANZ) and Leukaemia Foundation. She maintains a keen interest in clinical and translational research.
Dr Chee currently holds a Consultant Haematologist appointment at the Royal Melbourne Hospital Clinical Haematology and Bone Marrow Transplant Unit.
Dr Chee is proficient in the management of both benign and malignant haematological conditions and has a special interest in the treatment of acute and chronic leukaemia, lymphoma, myeloma, myelodysplasia and myeloproliferative disorders. She is also experienced in the field of autologous and allogeneic stem cell transplantation.
- Chee L, Spearing RL, Morris CM, McDonald M, Hanrahan V, Ebbett A, Scott R, Florkowski C, Walmsley T and Patton WN. Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): Evidence of engraftment without manifestation of ET in recipient. Bone Marrow Transplantation, 2005; 35: 1213-4.
- Chee L, Kalnins R and Turner P. Low dose melphalan in the treatment of myelofibrosis: a single centre experience. Leukemia and Lymphoma, 2006; 47: 1409-12.
- Chee L, Fahey V, Lieschke GJ, Juneja S and Szer J. Relapsed blastic natural killer cell leukaemia with splenic rupture. British Journal of Haematology, 2006; 135:2.
- Chee L, Brown M, Sasadeusz J, MacGregor L, Grigg AP. Gram negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies. Journal of Infection, 2008; 56: 227-33.
- Chee LCY, Hendy J, Purton L, and McArthur GA. ATRA and the RARα specific agonist, NRX195183, have opposing effects on the in vitro clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Blood (ASH Annual Meeting Abstracts), 2010; 116 (21): 999.
- Chee L, Hendy J, Purton LE, McArthur GA. The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARα) in the regulation of myeloid differentiation. Journal of Leukocyte Biology, 2012 Nov 7; doi:10.1189/jlb.1211609.
- Chee L, Hendy J, Purton LE, McArthur GA. ATRA and the RARα specific agonist, NRX195183, have opposing effects on the in vitro clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Leukemia 2012 Dec 11; doi: 10.1038/leu.2012.362
Professional Membership and Affiliations
- Haematology Society of Australia and New Zealand (HSANZ)
- Australasian Leukaemia and Lymphoma Group (ALLG)
- American Society of Hematology (ASH)
- Victorian Cooperative Oncology Group - Haemato-Oncology Committee
- Cancer Therapeutics Cooperative Research Centre (CRC)
- European Hematology Association
- ALLG Acute Leukaemia and Bone Marrow Transplant Disease Group Committees